Status:
TERMINATED
Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides
Lead Sponsor:
Swiss Tropical & Public Health Institute
Conditions:
Falciparum Malaria
Eligibility:
All Genders
18-30 years
Phase:
PHASE1
Brief Summary
Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept t...
Detailed Description
Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept t...
Eligibility Criteria
Inclusion
- Healthy volunteers of both sexes, aged between 18 and 45 years, with a BMI \> 18.5 and \<30 were included if they gave written informed consent
Exclusion
- Chronix or acute illness, immunosuppression, lived in the past in a malaria endemic area, had visited such an area in the last 12 months, or had a history of clinical malaria
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00400101
Start Date
November 1 2003
End Date
October 1 2005
Last Update
November 16 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.